Related Experiment Video
Updated: Jun 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Application in general practice of treatment guidelines for patients with dyslipidaemia: the RESPECT study
Patrice Cacoub1, Elisabeth Tocque-Le Gousse, Caroline Fabry
1Service médecine interne, groupe hospitalier La-Pitié-Salpêtrière, université Pierre-et-Marie-Curie Paris-VI, AP-HP, 47, boulevard de l'Hôpital, 75013 Paris, France. patrice.cacoub@psl.aphp.fr
Insights
French general practitioners widely use 2005 hypercholesterolaemia guidelines, improving cardiovascular risk assessment and patient awareness. This impacts therapeutic intervention thresholds and lipid-lowering drug use.
Area of Science:
- Cardiology
- General Practice
- Public Health
Background:
- Dyslipidaemia screening and management are vital for cardiovascular disease prevention.
- The impact of the 2005 French hypercholesterolaemia guidelines on general practitioners (GPs) remained unevaluated.
Purpose of the Study:
- To compare GPs' cardiovascular risk estimations with theoretical calculations.
- To analyze how risk estimation affects therapeutic intervention thresholds and target LDL-C.
- To assess patient awareness of their hypercholesterolaemia.
Main Methods:
- The RESPECT study was a multicentre, observational survey of 1797 GPs in France (March 2006-February 2007).
- Included were adults with primary hypercholesterolaemia not on lipid-lowering drugs for 6 months.
- Data collected included GP risk assessment, calculated risk, LDL-C targets, and patient awareness.
Main Results:
- GPs identified high, moderate, and low cardiovascular risk in 40.8%, 45.8%, and 13.4% of patients, versus calculated rates of 48%, 23%, and 29% (kappa concordance 59.4%).
- GPs' risk estimation significantly influenced therapeutic target LDL-C levels, lipid-lowering drug introduction, and follow-up visit frequency.
- Most patients felt informed about cholesterol, its causes/consequences, and the benefits of lipid-lowering drugs, emphasizing diet and treatment compliance.
Conclusions:
- The 2005 French hypercholesterolaemia guidelines are widely adopted by GPs.
- These guidelines facilitate accurate cardiovascular risk assessment and influence therapeutic decisions.
- Guideline implementation enhances patient understanding of cholesterol's relevance to cardiovascular health.
Background:
Screening for and management of dyslipidaemia are crucial in primary and secondary prevention of cardiovascular disease. The impact on general practitioners (GP) of the 2005 French guidelines for hypercholesterolaemia has not been evaluated.
Aims:
To compare GP's estimation of cardiovascular risk with that from a theoretical calculation; to analyse the consequences of cardiovascular-risk estimation on the threshold of therapeutic intervention and the target low-density lipoprotein cholesterol (LDL-C) concentration; and to analyse patients' awareness of their hypercholesterolaemia.
Methods:
The RESPECT study was a transverse, multicentre, observational survey conducted between March 2006 and February 2007 by 1797 GP in France. Inclusion criteria were adults with primary hypercholesterolaemia who had not taken lipid-lowering drugs within the previous 6 months.
Results:
Of the 5627 patients included (60.9% men; mean age+/-standard deviation 58.2+/-11.0 years; body mass index 27.2+/-4.1 kg/m(2); mean total cholesterol 2.68+/-0.37 g/L; LDL-C 1.79+/-0.35 g/L), 1963 (36.2%) had at least three cardiovascular risk factors. GP identified a high cardiovascular risk level in 40.8%, moderate risk in 45.8% and low risk in 13.4% of patients. These compared with calculated rates of 48, 23 and 29%, respectively (kappa concordance 59.4%). For most patients (98.2%), GP defined the therapeutic target based on LDL-C concentration. The target LDL-C was significantly different when cardiovascular risk was estimated by GP versus that calculated theoretically. The higher the estimated risk level, the greater the rate of introduction of lipid-lowering drugs and the shorter the time to the next GP visit. Most patients considered themselves to be well or rather well informed about their cholesterol concentration (91.3%), the causes (64.3%) and consequences of cholesterol-induced diseases (83.7%), and the difference between 'good' and 'bad' cholesterol (57%). Most (81.5%) patients were aware of the benefits of lipid-lowering drugs on cardiovascular disease prevention; 95.8% considered adequate diet and compliance with pharmacological treatment to be very important.
Conclusion:
Recent French guidelines for hypercholesterolaemia are used widely by GP in practice. They enable correct assessment of overall cardiovascular risk level, have an impact on the therapeutic threshold of intervention by physicians and improve patients' awareness of the relevance of cholesterol concentration.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Peripheral Artery Disease III: Interprofessional Care
Lipids: Dietary Sources and Requirements
Angina IV: Management